The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 ...

Livingwell Medical Center accepts most major insurance plans but also offers affordable self-pay rates for patients without ...

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...

Researchers say payers should take the added costs of drugs prescribed to deal with GLP-1 side effects into account when ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The FDA's new rule restricting the sale of compounded semaglutide could make it more difficult for some people to obtain ...

After Hims & Hers (HIMS) announced yesterday that the company is broadening its weight loss offering to include Lilly’s (LLY) branded ...

Citi analyst Daniel Grosslight says Hims & Hers traded up 10% yesterday after Bloomberg noted the company is now offering branded ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from 2022 to 2023. Although spending for certain GLP-1 RAs increased ...